科學+家 復發研究 | SCIENTIST HOME Recurrent Study

復發

為了可靠地治癒癌症，局部控制是必不可少的。然而，局部復發（LRR）是許多惡性腫瘤中臨床相關的主要失敗模式。本文綜述了現時預防和治療6種惡性腫瘤局部復發的治療策略：直腸癌、乳腺癌、間皮瘤、非小細胞肺癌、腹膜後肉瘤和腹膜表面惡性腫瘤（圖1，錶1）。手術切除後的局部復發對這些癌症患者的生存率和生活質量起著重要作用。此外，這些惡性腫瘤代表了一系列重要的腫瘤學原則，在評估治療和預防局部復發的當前和未來療法時需要考慮。強調局部復發的模式和危險因素。https://www.ncbi.nlm.nih.gov/pmc/articles/PMC62398...

科學+家 復發研究

可能適合多學科復康調理:

• 抑制细胞增殖(1)
• 誘導細胞凋亡(2)
• 抑制血管生成(2)
• 改善生活質量(3)
• 顯著改善所有參數(4)
• 誘導細胞死亡(5)
  

食用建议：在需要的時期，空腹飲用，每日3次；每次一平量匙，250 毫升溫水沖開後飲用；兩餐中間或饭前 1 小时前食用。

劑形及包装：粉状，1樽105克

份量：7天

產地：中國香港

重要提示:

不適用於以下情况：

• 懷孕或哺乳期
• 18歲以下兒童

主要成份: 肌醇六磷酸，植酸，紫檀烯，羥基二苯乙烯，和厚樸酚（C18H18O2），胡帕提取物，肌醇，丹波糖，乳鐵蛋白，初乳，穿心蓮內酯，三棱根提取物，薯蕷皂甙，鹽芥醇提取物。

Recurrence

In order to cure cancer reliably, local control is essential. However, local recurrence (LRR) is a clinically relevant major failure mode in many malignancies. This article reviews the current treatment strategies for the prevention and treatment of local recurrence of six kinds of malignant tumors: rectal cancer, breast cancer, mesothelioma, non-small cell lung cancer, retroperitoneal sarcoma and peritoneal surface malignant tumors (Fig. 1, table 1). Local recurrence after surgical resection plays an important role in the survival rate and quality of life of these cancer patients. In addition, these malignancies represent a number of important oncological principles that need to be considered when evaluating current and future therapies for treatment and prevention of local recurrence. The pattern and risk factors of local recurrence were emphasized. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC62398...

It may be suitable for multidisciplinary rehabilitation:

• Inhibition of cell proliferation (1)
• Inducing apoptosis (2)
• Inhibition of angiogenesis (2)
• Improving the quality of life (3)
• Significant improvement in all parameters (4)
• Inducing cell death (5)

Consumption: when necessary, drink it on an empty stomach, three times a day; one teaspoon for each time, drink it after 250 ml warm water is boiled; take it between meals or 1 hour before meals.

Package: powder, 105g/ bottle

Serving size: 7 days

Origin: Hong Kong, China

Important Note

1. Not suitable if:
   1. Pregnant or lactating.
   2. Children under 18 years of age.

Major Ingredients: IP6, Inositol Hexakisphosphate, Phytate, Pterostilbene, Hydroxystilbene, Honokiol (C18H18O2), Houpa Extract, Inositol, Dambose, Lactoferrin, Colostrum, Andrographolide, Rhizoma Sparganii Extract, Diosmetin, Salinigricoflavonol Extract.

參考文獻 Refs:

1. 1.Xiangyu Luo, Weimin Luo, Chenyi Lin, Li Zhang, and Yaling Li. Andrographolide inhibits proliferation of human lung cancer cells and the related mechanisms. Int J Clin Exp Med. 2014; 7(11): 4220–4225. Published online 2014 Nov 15. PMCID: PMC4276192 PMID: 25550934
2. Jia Hu ¹ , Li Juan Chen, Li Liu, Xiang Chen, Ping Li Chen, Guang Yang, Wen Li Hou, Ming Hai Tang, Fan Zhang, Xian Huo Wang, Xia Zhao, Yu Quan Wei Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity. Exp Mol Med. 2008 Dec 31;40(6):617-28. doi: 10.3858/emm.2008.40.6.617. PMID: 19116447. PMCID: PMC2679338
3. Tarek M. Moastafa, ¹ Alaa El-Din Elsayed El-Sissy, ² Gehan K. El-Saeed, ³ and Mai Salah El-Din Koura ^{4 , *} Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy. Journal List. Int Sch Res Notices. v.2014; 2014. PMC4897438. Int Sch Res Notices. 2014; 2014: 184278. Published online 2014 Oct 28. doi: 10.1155/2014/184278. PMCID: PMC4897438. PMID: 27350986
4. Raghupathy Vengoji,¹ Muzafar A. Macha,^1,2 Surinder K. Batra,^1,3 and Nicole A. Shonka^3,4 Natural products: a hope for glioblastoma patients. Journal List. Oncotarget. v.9(31); 2018 Apr 24. PMC5955138. Oncotarget. 2018 Apr 24; 9(31): 22194–22219. Published online 2018 Apr 24. doi: 10.18632/oncotarget.25175. PMCID: PMC5955138. PMID: 29774132
5. Ivan Bačić,¹ Nikica Družijanić,² Robert Karlo,¹ Ivan Škifić,¹ and Stjepan Jagić³ Efficacy of IP₆ + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study. J Exp Clin Cancer Res. 2010; 29(1): 12. Published online 2010 Feb 12. doi: 10.1186/1756-9966-29-12. PMCID: PMC2829500. PMID: 20152024

This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.